Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27324837 | 1.00 | LOXL2 (0.59) | LOXL2DPP4CASRHTR2AHTR2C | |
| Acetic Acid SCHEMBL5533726 | 0.91 | MTNR1A (0.52) | LOXL2DPP4 | |
| SCHEMBL9027554 | 0.85 | LOXL2 (0.58) | LOXL2DPP4CASRHRH4 | |
| SCHEMBL14680760 | 0.83 | DPP4 (0.54) | LOXL2DPP4CASRTAAR1HRH4 | |
| SCHEMBL3886864 | 0.83 | DPP4 (0.57) | LOXL2DPP4CASRHTR2AHRH4 | |
| SCHEMBL5249054 | 0.82 | LOXL2 (0.55) | LOXL2DPP4CASRHRH4 | |
| SCHEMBL30305027 | 0.82 | LOXL2 (0.55) | LOXL2DPP4CASRHRH4 | |
| SCHEMBL5365001 | 0.82 | LOXL2 (0.55) | LOXL2DPP4CASRHRH4 | |
| SCHEMBL18348897 | 0.81 | LOXL2 (0.54) | LOXL2DPP4CASRHRH4AOC3 | |
| SCHEMBL12936626 | 0.79 | MTNR1A (0.54) | LOXL2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245161-A2 | CATIONIC NONRIBOSOMAL LIPOPEPTIDES AND METHODS OF USE THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4282867-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-109311876-B | Heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3472162-B1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| EP-3472162-B1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3472162-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2010030342-A2 | HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERAPEUTICS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-1756054-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2005118539-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-0453517-A1 | BREATHABLE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 1991-10-30 | — | — | EP | disclosed |
| WO-1990007939-A1 | BREATHABLE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 1990-07-26 | — | — | WO | disclosed |
| US-4343802-A | ADRENERGIC BLOCKING, ANTIARRYHYTHMIA, AND CARDIOTONIC AGENTS | MERCK, SHARP & DOHME (I.A.) CORP. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4193995-A | B-ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4042586-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
| US-3946009-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002344-A1 | HETEROARYL ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRA | LOXL2 919/4885DPP4 2631/4885CASR 423/4885 |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | LOXL2 3387/4885DPP4 1235/4885CASR 2198/4885 |
| US-10654867-B2 | Heteroaryl estrogen receptor modulators and uses thereof | ESR2, GPER1, ESRRA | LOXL2 919/4885DPP4 2631/4885CASR 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.